# Insulin Degludec and Glargine U100 for Management of Hospitalized and Discharged Patients With Type 2 Diabetes

> **NCT03336528** · PHASE4 · COMPLETED · sponsor: **Emory University** · enrollment: 180 (actual)

## Conditions studied

- Type 2 Diabetes

## Interventions

- **DRUG:** Degludec
- **DRUG:** Glargine
- **DRUG:** Aspart

## Key facts

- **NCT ID:** NCT03336528
- **Lead sponsor:** Emory University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-01-02
- **Primary completion:** 2021-03-01
- **Final completion:** 2021-03-01
- **Target enrollment:** 180 (ACTUAL)
- **Last updated:** 2022-03-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03336528

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03336528, "Insulin Degludec and Glargine U100 for Management of Hospitalized and Discharged Patients With Type 2 Diabetes". Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/clinical/NCT03336528. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*